Journal articlePLoS One2024

Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer.

DOI 10.1371/journal.pone.0301271 ↗ PubMed Central open-access subset, retrieved 5 November 2026

Journal: PLoS One
Published: 4 April 2024
Citations: 2
Type: Article
License: cc by
Full text: Open access, reuse-licensed (cc by)

These are the paper’s bibliographic details. A summary of its population, design, endpoints and findings, each tied to a quote, has not been written for this paper yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Its licensed text is not loaded here yet, so most questions will be declined.

Try